Johnson & Johnson has released its second quarter results, which revealed announced sales of $16.5 billion (£10.5 billion).
This figure marks a 0.7 per cent decrease when compared to the same time last year, but operational results jumped 3.5 per cent, while the negative impact of currency stood at 4.2 per cent.
Alex Gorsky, chief executive officer of the company, said: "Our pharmaceutical pipeline continued its strong momentum this quarter with the submission of several new drug applications, as well as strong growth from several recently launched products that meet critical patient needs."
The results also showed worldwide consumer sales of $3.6 billion for the quarter, marking a drop of 4.6 per cent when compared to the preceding year.
In recent months, Johnson & Johnson purchased Synthes in a bid to widen its range of clinical research projects.
The company was bought for $19.7 billion in cash and stock and it will be incorporated alongside the DePuy Franchise, forming DePuy Synthes Companies of Johnson & Johnson.